Shuttle Pharma doses three subjects in Phase II glioblastoma treatment trial
Shuttle Pharmaceuticals (Shuttle Pharma) has dosed the first three participants in a Phase II trial of its lead therapy, Ropidoxuridine, …
Post
-
-
ARIA-E risk of Lilly’s Kisunla in Alzheimer’s reduced with modified dosing
A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related imaging abnormalities with …
-
Spero’s stock slides after antibiotic flops in Phase II trial
Spero Therapeutics has suspended the development of its antibiotic SPR720, after the therapy failed to meet the primary endpoint in a Phase …
-
Sagimet’s denifanstat enters Phase III trials for MASH treatment
Sagimet Biosciences has announced the progression of its lead candidate, denifanstat, an oral, selective fatty acid synthase (FASN) inhibitor, into …
-
Zai Lab presents positive outcomes from KarXT Phase III trial for schizophrenia
Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT (xanomeline and trospium chloride) in China …
-
DACH region an “attractive place” to conduct clinical trials despite strict EU laws
Despite stringent European Union (EU) laws governing smaller medical device and pharma companies, the DACH region can be an attractive …
-
Arrivo targets major depressive disorder in females after early efficacy data
Arrivo BioVentures’ SIRT6 activator SP-624 has been found to significantly reduce symptoms of major depressive disorder (MDD), but only in …
-
START and Fundación Rioja Salud to expand access to cancer drug trials in Spain
The US-based START Center for Cancer Research (START) has signed a strategic collaboration with the Spanish Fundación Rioja Salud foundation …
-
First participants dosed in trial of long-acting malaria preventative
Medicines for Malaria Venture (MMV) and Quotient Sciences have dosed the first participants in a trial of MMV371, a long-acting …
-
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
Johnson & Johnson (J&J) and Eli Lilly have both revealed the efficacy of their interleukin-23 (IL-23) inhibitors to treat Crohn’s …
-
Bavarian eyes mpox vaccine label expansion to include toddlers, kickstarts Phase II trial
Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children between two and …
-
US Border Protection warns pharma of risks with incorrect biologic importation
The incorrect transport of biological materials opens the US up to risk of infectious disease and biological threats, says Sean …
-
Shockwave Medical enrols all subjects in study of PCI to treat calcified lesions
US-based medical device company Shockwave Medical has finished enrolling subjects in the EMPOWER CAD study of percutaneous coronary intervention (PCI) …
-
Debunking five misconceptions about community-based research sites in clinical trials
Clinical trials often face significant challenges in recruiting and retaining diverse participants, which can lead to skewed data and less …
-
Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer
Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in …
